Thrombopoietin Receptor (TPO)

Avatrombopag is a novel orally-active thrombopoietin (TPO) receptor agonist.

TPO agonist 1 can increase production of platelets by stimulating the TPO receptor in people with chronic ITP.

Lusutrombopag, also known as S-888711, is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist being developed by Shionogi for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery.